Studies have shown that these drugs can stimulate tumor cells to release tumor antigens, upregulate co-inhibitory ligands such as PD-L1 in malignant cells or tumor-infiltrating lymphocytes, and enhance dendritic cell activation and PD-L1 expression, ultimately influencing the effects of ICIs. The gene discussed is CD274; the disease is neoplasm.